Undisclosed Bispecific ADC (ArbeleBio)

This undisclosed bispecific antibody-drug conjugate (ADC) is a preclinical asset being developed by ArbeleBio for the treatment of CDH17-positive tumors, particularly gastrointestinal cancers. The molecule is designed to target Cadherin-17 (CDH17) along with a second, undisclosed antigen or epitope. CDH17 is a cell adhesion protein that is highly overexpressed in various gastrointestinal malignancies, including colorectal, gastric, and pancreatic cancers, while maintaining restricted expression in healthy tissues. By utilizing a bispecific targeting approach, the ADC aims to enhance tumor selectivity and facilitate efficient internalization of the cytotoxic payload, thereby potentially improving the therapeutic window and reducing off-target toxicities compared to traditional monoclonal ADCs.

Other names

Arbele CDH17 Bispecific ADCCDH17-targeted bispecific ADCCDH-17-targeted bispecific ADCCDH 17-targeted bispecific ADC